NCT01718366 - A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions

MDS

Interventions

DRUG

Deferasirox, Vitamin D and Azacitidine

association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)

Trial Locations (15)

9000

GENT, Ghent

44093

CHU Nantes, Nantes

54511

CHU Brabois, Nancy

59020

Hôpital Saint Vincent de Paul, Lille

64100

Centre Hospitalier de La Cote Basque, Bayonne

75010

Hôpital saint Louis, Paris

75679

Hôpital cochin, Paris

75743

Hôpital Necker, Paris

86021

CHU Poitiers, Poitiers

87042

CHU Limoges, Limoges

93009

Hôpital Avicenne, Bobigny

Unknown

Centre Hospitalier de Boulogne sur Mer, Boulogne-sur-Mer

CHU Le Mans, Le Mans

Centre Catherine de Sienne, Nantes

IUCT Oncopole Toulouse, Toulouse